Details of the Drug

General Information of Drug (ID: DMEXNZN)

• Drug Name: GL-ONC1
• Synonyms: olvimulogene nanivacirepvec

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
Ovarian cancer	2C73	Phase 1/2	[2]
Peritoneal carcinomatosis	2D91	Phase 1/2	[3]
Peritoneal cavity cancer	2C51.Z	Phase 1	[1]

• Drug Type: Oncolytic virus therapy
• Cross-matching ID:
  UNII: CF19SF72O5
  DrugBank ID: DB16268
  TTD ID: DA6OU0
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02759588) GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)